TheraRadar
← Back
Data updated: Jun 28, 2026

ROBERTS OXYGEN CO INC

Pharma
Pharmaceuticals

ROBERTS OXYGEN CO INC is a pharmaceutical company with 2 FDA-approved products.

2019
Since
2
Drugs
-
Trials
6
New Drugs (2yr)
Modality:
2 Small Molecules

ROBERTS OXYGEN CO INC's Key Drugs

ROBERTS OXYGEN CO INC's core commercial portfolio centers on HELIUM, USP, CARBON DIOXIDE, USP — its most strategically important drugs approved in the last 15 years.

HELIUM, USP
Respiratory
Approved 2013
CARBON DIOXIDE, USP
Respiratory
Approved 2013

ROBERTS OXYGEN CO INC's Recent FDA Approvals

ROBERTS OXYGEN CO INC secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

CARBON DIOXIDE, USP NDA
2025-10-25
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-06-16
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-04-21
carbon dioxide
Carbon Dioxide, USP NDA
2025-02-02
carbon dioxide
Carbon Dioxide, USP NDA
2024-11-09
carbon dioxide, usp
CARBON DIOXIDE, USP NDA
2024-08-10
carbon dioxide

ROBERTS OXYGEN CO INC's Therapeutic Areas

Disease areas where ROBERTS OXYGEN CO INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

ROBERTS OXYGEN CO INC Pipeline Snapshot

Active clinical trials for ROBERTS OXYGEN CO INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • HELIUM, USP leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling